ASTEPRO 0.15%—the Earlier the Better

Compared with selected prescription antihistamines, ASTEPRO 0.15% offers the highest Tier 2 availability under commercial managed care plans*

  • Eligible, insured patients who may need additional savings can use the Instant Savings Card to limit their prescription and refill copays to $25 through December 31, 2012
  • ASTEPRO 0.15% is available without restriction on 93% of covered lives
 

e-Newsletter

Coming soon! Sign up for our healthcare professionals email series

View FAQs

Comparison Chart

Product Overview

 

Patanase is a registered trademark of Alcon, Inc. Clarinex is a registered trademark of the Schering Corporation.
*Data on file. Meda Pharmaceuticals Inc; June, 2011. Percentage based upon formulary coverage under commercial managed care organizations.
†For eligible, insured patients only. Coupon covers the balance of the copay over $25 (if any) for the first unit dispensed and for refills. Maximum value of $100 per dispensed unit.
Offer expires December 31, 2012. Please see full program terms and conditions on the back of the Instant Savings Card brochure or visit http://www.astepro.com/patients/termsandconditions.html.

Indication

ASTEPRO® (azelastine HCl) Nasal Spray 0.15% is indicated for the relief of the symptoms of seasonal and perennial allergic rhinitis in patients 12 years of age and older.

Important Risk Information

  • Avoid engaging in hazardous occupations requiring complete mental alertness when taking ASTEPRO Nasal Spray 0.15%
  • Avoid concurrent use of alcohol or other central nervous system depressants with ASTEPRO Nasal Spray 0.15%
  • In clinical studies, the most commonly reported adverse reactions, when dosed at 2 sprays per nostril once or twice daily, respectively, included bitter taste (4%, 6%), nasal discomfort (4%, 3%), epistaxis (2%, 1%), and sneezing (1%, 2%)
  • Pregnancy Category C: Based on animal data, may cause fetal harm
    Please see full Prescribing Information
    You are encouraged to report negative side effects of prescription drugs to the FDA.
    Visit www.fda.gov/medwatch, or call 1‐800‐FDA‐1088